This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.
Masimo's (MASI) EMMA Capnography on Neonates Favored by New Study
by Zacks Equity Research
Masimo's (MASI) EMMA is likely to aid in maintaining an optimal range of PaCO2 in preterm infants undergoing mechanical ventilation in the neonatal intensive care unit.
Baxter's (BAX) Premix Norepinephrine Now Available in U.S.
by Zacks Equity Research
Baxter's (BAX) norepinephrine can improve speed, efficiency and safety of treatment during critical care situations in hospital settings, and minimize compounding errors or touch contamination risks.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.
NextGen's (NXGN) New Partnership to Boost Patient Experience
by Zacks Equity Research
NextGen (NXGN) collaborates with Clinect Healthcare to extend patient-provider connection.
Here's Why You Should Hold on to LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from strategic deals and broad array of services.
Veeva Systems' (VEEV) Cloud Applications Get Adopted by Emmes
by Zacks Equity Research
Veeva Systems' (VEEV) Development Cloud applications to aid in connected drug development.
Here's Why You Should Retain Inogen (INGN) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
PacBio (PACB) Closes Omniome Buyout, Forays Into San Diego
by Zacks Equity Research
PacBio's (PACB) latest acquisition is expected to deliver a differentiated set of products and applications across a wide spectrum of markets.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.
Fresenius Medical's (FMS) Deal to Boost Home Dialysis in Japan
by Zacks Equity Research
Fresenius Medical (FMS) partners with JMS Co. Ltd. to provide innovative home dialysis therapies to the aging population in Japan to improve their wellbeing.
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Abiomed (ABMD) owing to its strength in the Impella product line.
PerkinElmer (PKI) to Benefit From BioLegend Buyout: Here's How
by Zacks Equity Research
PerkinElmer's (PKI) latest acquisition is likely to expand its life science business and enhance its reagents portfolio.
Henry Schein (HSIC) Betters Strategic View With Restructure Plan
by Zacks Equity Research
Henry Schein's (HSIC) new organizational structure will continue to enhance the company's exposure to faster-growing and higher-margin markets.
NextGen's (NXGN) New Collaboration to Boost Solutions Portfolio
by Zacks Equity Research
NextGen (NXGN) and Klamath partner to deliver large-scale COVID-19 vaccinations.
Cybersecurity Gains Prominence in MedTech: 3 Stocks to Focus on
by Debanjana Dey
Technology-based healthcare stocks like Henry Schein (HSIC), Veeva Systems (VEEV) and BD (BDX) are expected to continue their rally over the next few months.
Align Technology (ALGN) Launches Professional Whitening System
by Zacks Equity Research
Align Technology's (ALGN) Invisalign Professional Whitening System transforms teeth whitening with an all-in-one solution, enabling Invisalign doctors to straighten and whiten teeth simultaneously.
The Zacks Analyst Blog Highlights: Align Technology, West Pharmaceutical Services, Henry Schein and Merit Medical Systems
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Align Technology, West Pharmaceutical Services, Henry Schein and Merit Medical Systems
Syneos Health's (SYNH) New Buyout Boosts Clinical Solutions Arm
by Zacks Equity Research
Syneos Health (SYNH) acquisition of StudyKIK strengthens the former's ability to provide technology and insight-driven solutions.
Here's Why You Should Retain Catalent (CTLT) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.
3 Dental Stocks Poised to Perform Well in Second-Half 2021
by Trina Mukherjee
Let's keep a watch on three lucrative stocks, WST, HSIC and MMSI, in the dental space that investors can add to their watchlist backed by robust long-term prospects.
Accuray's (ARAY) CyberKnife Favored For Prostate Cancer Treatment
by Zacks Equity Research
Per the PACE trial data, patients treated with Accuray's (ARAY) CyberKnife SBRT are likely to experience lesser bladder-related side effects unlike conventional linear accelerator.
OPKO Health (OPK) Forms JV, Establishes Presence in China
by Zacks Equity Research
OPKO Health (OPK) forms a new JV with LeaderMed to establish a presence in China through expansion of the global availability of two of the former's long-acting development products.
Medtronic's (MDT) Pilot Plan to Address SCA Care Disparities
by Zacks Equity Research
Medtronic's (MDT) pilot program offers an advanced and scalable method to use real-world clinical data which enable quicker and appropriate care for patients at-risk of SCA.
Dexcom's (DXCM) G6 CGM Under NIHB Program to Aid More Patients
by Zacks Equity Research
Expanded access to Dexcom's (DXCM) G6 CGM for clients enrolled in NIHB is expected to aid a wider patient pool to better manage their diabetes.